All posts by: Michael Zand

About Michael Zand

Novartis says US regulator grants speedy review of CAR-T cell therapy – Reuters

Continue reading

2017-03-30 NEWS

Reuters

Novartis says US regulator grants speedy review of CART cell therapy
Reuters
The move would keep Novartis on track with the development of its so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers. The therapy involves a patient’s own Tcells being altered in
Novartis Makes Plans For Its Cancer-Killing T CellsForbes
Novartis Says CART Cell Therapy BLA Granted FDA Priority ReviewNasdaq
Does the drama of the CART race actually matter?STAT
MedCity News –Endpoints News –Healio
all 10 news articles »
Continue reading

2017-03-30 NEWS

Forbes

Novartis says US regulator grants speedy review of CART cell therapy
Reuters
The move would keep Novartis on track with the development of its so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers. The therapy involves a patient’s own Tcells being altered in
Novartis Makes Plans For Its Cancer-Killing T CellsForbes
Novartis gets speedy review for CART cell therapyPharmaTimes
Novartis Says CART Cell Therapy BLA Granted FDA Priority ReviewNasdaq
pharmaphorum –STAT –MedCity News
all 15 news articles »
Continue reading

2017-03-30 NEWS

Stem cells A case of metabolic identity in the intestinal crypt
Nature.com
How does metabolism contribute to epithelial renewal in the intestinal crypt? According to a new study published in Nature, LGR5+ crypt base columnar cells (CBCs) and Paneth cells — key constituents of the intestinal stem cell niche — have different …

Continue reading

2017-03-29 NEWS

Forbes

Novartis Makes Plans For Its Cancer-Killing T Cells
Forbes
There’s a race on to be the first company to launch what’s a CAR-T — a technology that genetically alters cancer patients’ white blood cells to kill tumor cells. (It stands for chimeric antigen receptor Tcell, which means “white blood cells with
Novartis Says CART Cell Therapy BLA Granted FDA Priority ReviewNasdaq
First come, first served: Novartis finalizes CART application, claims priority reviewMedCity News
Does the drama of the CART race actually matter?STAT
Endpoints News –Healio
all 7 news articles »
Continue reading

2017-03-29 NEWS

Endpoints News

Novartis announces first CART cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted
Yahoo Finance
CAR-T is different from typical small molecule or biologic therapies currently on the market because it is manufactured for each individual patient. During the treatment process, T cells are drawn from a patient’s blood and reprogrammed in the
Novartis gets a speedy review for its CART pioneer as FDA lines up a marketing decisionEndpoints News
Does the drama of the CART race actually matter?STAT
FDA grants priority review to CTL019 for ALLHealio

all 4 news articles »